Nav: Home

Pioneering research on mechanistic basis of disease in new journal Systems Medicine

March 13, 2018

New Rochelle, NY, March 13, 2018--The new peer-reviewed journal, Systems Medicine, has launched with a powerful mission to capture the leading research in the emerging field of medical systems biology. A fascinating Roundtable Discussion with key opinion leaders on the importance of systems medicine and interviews with thought leaders highlight the debut of Systems Medicine, a new open access journal from Mary Ann Liebert, Inc., publishers. The articles are available on the Systems Medicine website.

Co-Editors-in-Chief Harald H.H.W. Schmidt, MD, PhD, PharmD, Maastricht University, The Netherlands and Jan Baumbach, PhD, Technical University of Munich, Germany, discuss why the current approach to treating disease fails to drive successful new drug development in their Editorial entitled, "The End of Medicine as We Know It: Introduction to the New Journal, Systems Medicine." Modern omics technology is providing a new way to look at diseases and, combined with advanced molecular tools, a deeper understanding of systems biology, and big data, is enabling new mechanistic definitions of disease.

In an insightful Roundtable Discussion moderated by Dr. Schmidt, the expert panel examines the differences between systems medicine and current medicine and share their views on how systems medicine can help solve some of the problems plaguing classical medicine. Roundtable participants Jan Baumbach, Joseph Loscalzo, Alvar Agusti, Edwin Silverman, and Vasco Azevedo explore how an emphasis on molecular mechanistic biomarkers will help drive major innovations in new drug discovery and the development of novel preventive therapies based on research into the trajectories of healthy aging.

Newly published in Systems Medicine are interviews with two thought leaders on systems medicine: Charles Auffray, PhD, President, European Institute for Systems Biology & Medicine and Chair of the Executive Board, European Association of Systems Medicine, and Weiniu Gan, PhD, Program Director, Division of Lung Diseases, National Heart, Lung, and Blood Institute, U.S. National Institutes of Health.
About the Journal

Systems Medicine: Journal of Medical Systems Biology and Network Medicine is the premier open access, peer-reviewed journal focused on interdisciplinary approaches to exploiting the power of big data by applying systems biology and network medicine. Led by Co-Editors-in-Chief H.H.H.W. Schmidt, MD, PhD, PharmD, Maastricht University, and Jan Baumbach, PhD, Technical University of Munich, Germany, Systems Medicine yields major breakthroughs towards mechanism-based re-definitions of diseases for high-precision diagnostics and treatments. The Journal is collaborative partners with the European Cooperation in Science and Technology (COST), Italian Association for Systems Medicine and Healthcare (ASSIMSS), and European Association for Systems Medicine (EASYM). Complete tables of content can be viewed on the Systems Medicine website.

About the Publisher

Mary Ann Liebert, Inc., publishers is a privately held, fully integrated media company known for establishing authoritative peer-reviewed journals in many promising areas of science and biomedical research, including Assay and Drug Development Technologies, Big Data, and OMICS: A Journal of Integrative Biology. Its biotechnology trade magazine, GEN (Genetic Engineering & Biotechnology News), was the first in its field and is today the industry's most widely read publication worldwide. A complete list of the firm's 80 journals, books, and newsmagazines is available on the Mary Ann Liebert, Inc., publishers website.

Mary Ann Liebert, Inc./Genetic Engineering News

Related Drug Discovery Articles:

Choosing a simpler path to drug discovery
Researchers from Kyoto University, MIT, and ETH Zurich have developed a compact drug discovery method using simple models and small data sets.
Drug discovery researchers awarded grant to refine malaria drug
A research team from the Virginia Tech Center for Drug Discovery has received a $431,126 two-year grant from the National Institutes of Health to make improved versions of a promising compound called MMV008138, or 8138 for short.
New computational tool may speed drug discovery
A new computational tool called fABMACS is helping scientists see beyond static images of proteins to more efficiently understand how these molecules function, which could ultimately speed up the drug discovery process.
Paving the road to drug discovery
When treated with an anti-cancer drug, ICRF-193, fission yeast produce an 'arched and snapped' phenotype that may be used to screen for other cancer drugs.
Open-source drug discovery a success
In what is being called the first-ever test of open-source drug-discovery, researchers from around the world have successfully identified compounds to pursue in treating and preventing parasite-borne illnesses such as malaria as well as cancer.
Celgene joins DNDi's 'Drug Discovery Booster'
The biopharmaceutical company Celgene has become the fifth company to join the 'Neglected Tropical Diseases Drug Discovery Booster' consortium, a new initiative to accelerate and cut the cost of early stage drug discovery for two of the world's most neglected diseases, leishmaniasis and Chagas disease.
Speeding up drug discovery to fight tuberculosis
Researchers at the Institute for Systems Biology and Center for Infectious Disease Research in Seattle have deciphered how the human pathogen Mycobacterium tuberculosis is able to tolerate the recently approved FDA drug bedaquiline.
Deep learning applied to drug discovery and repurposing
Scientists from Insilico Medicine in collaboration with Datalytic Solutions and Mind Research Network trained deep neural networks to predict the therapeutic use of large number of multiple drugs using gene expression data obtained from high-throughput experiments on human cell lines.
Breast cancer drug discovery offers hope of new treatments
A new drug discovery approach has yielded a potential therapy for breast cancer that may be more effective than existing medicines.
Current cancer drug discovery method flawed: Study
The primary method used to test compounds for anti-cancer activity in cells is flawed, Vanderbilt University researchers report May 2 in Nature Methods.

Related Drug Discovery Reading:

Drugs: From Discovery to Approval
by Rick Ng (Author)

The third edition of this best-selling book continues to offer a user-friendly, step-by-step introduction to all the key processes involved in bringing a drug to the market, including the performance of pre-clinical studies, the conduct of human clinical trials, regulatory controls, and even the manufacturing processes for pharmaceutical products. 

Concise and easy to read, Drugs: From Discovery to Approval, Third Edition quickly introduces basic concepts, then moves on to discuss target selection and the drug discovery process for both small and large molecular drugs. The... View Details

Basic Principles of Drug Discovery and Development
by Benjamin Blass (Author)

Basic Principles of Drug Discovery and Development presents the multifaceted process of identifying a new drug in the modern era, providing comprehensive explanations of enabling technologies such as high throughput screening, structure based drug design, molecular modeling, pharmaceutical profiling, and translational medicine, all areas that have become critical steps in the successful development of marketable therapeutics.

The text introduces the fundamental principles of drug discovery and development, also discussing important drug targets by class, in vitro screening... View Details

Drug Discovery and Development: Technology in Transition, 2e
by Raymond G Hill (Editor)

The modern pharmacopeia has enormous power to alleviate disease, and owes its existence almost entirely to the work of the pharmaceutical industry. This book provides an introduction to the way the industry goes about the discovery and development of new drugs. The first part gives a brief historical account from its origins in the mediaeval apothecaries’ trade, and discusses the changing understanding of what we mean by disease, and what therapy aims to achieve, as well as summarising case histories of the discovery and development of some important drugs. The second part focuses on the... View Details

Bioinformatics and Computational Biology in Drug Discovery and Development
by William T. Loging (Editor)

Computational biology drives discovery through its use of high-throughput informatics approaches. This book provides a road map of the current drug development process and how computational biology approaches play a critical role across the entire drug discovery pipeline. Through the use of previously unpublished, real-life case studies the impact of a range of computational approaches are discussed at various phases of the pipeline. Additionally, a focus section provides innovative visualisation approaches, from both the drug discovery process as well as from other fields that utilise large... View Details

Drug Discovery: A History
by Walter Sneader (Author)

Written by a leading authority with an excellent reputation and ability for writing a good narrative, Drug Discovery: A History is a far cry from simply a list of chemical structures.

This lively new text considers the origins, development and history of medicines that generate high media interest and have a huge social and economic impact on society.

Set within a wide historical, social and cultural context, it provides expanded coverage of pre-twentieth century drugs, the huge advances made in the twentieth century and the latest developments in drug research.

... View Details

Drug Discovery: Practices, Processes, and Perspectives
by Jie Jack Li (Editor), E. J. Corey (Editor)

Sets forth the history, state of the science, and future directions of drug discovery

Edited by Jie Jack Li and Nobel laureate E. J. Corey, two leading pioneers in drug discovery and medicinal chemistry, this book synthesizes great moments in history, the current state of the science, and future directions of drug discovery into one expertly written and organized work. Exploring all major therapeutic areas, the book introduces readers to all facets and phases of drug discovery, including target selection, biological testing, drug metabolism, and computer-assisted drug... View Details

Drugs: From Discovery to Approval
by Rick Ng (Author)

"Concise and easy to read, the book quickly introduces basic concepts, then moves on to discuss target selection and the drug discovery process for both small and large molecular drugs."
Doody's Reviews, May 2009

"The second edition of a book that offers a user-friendly step-by-step introduction to all the key processes involved in bringing a drug to the market, including the performance of preclinical trials."
Chemistry World, February 2009

The new edition of this best-selling book continues to offer a user-friendly, step-by-step... View Details

Pharmacology in Drug Discovery and Development, Second Edition: Understanding Drug Response
by Terry Kenakin (Author)

Pharmacology in Drug Discovery and Development: Understanding Drug Response, Second Edition, is an introductory resource illustrating how pharmacology can be used to furnish the tools necessary to analyze different drug behavior and trace this behavior to its root cause or molecular mechanism of action. The concepts discussed in this book allow for the application of more predictive pharmacological procedures aimed at increasing therapeutic efficacy that will lead to more successful drug development.

Chapters logically build upon one another to show how to characterize the... View Details

Mass Spectrometry for Drug Discovery and Drug Development
by Walter A. Korfmacher (Editor)

Facilitates the discovery and development of new, effective therapeutics

With coverage of the latest mass spectrometry technology, this book explains how mass spectrometry can be used to enhance almost all phases of drug discovery and drug development, including new and emerging applications. The book's fifteen chapters have been written by leading pharmaceutical and analytical scientists. Their contributions are based on a thorough review of the current literature as well as their own experience developing new mass spectrometry techniques to improve the ability to discover... View Details

The Evolution of Drug Discovery
by Enrique Ravina (Author), Hugo Kubinyi (Foreword)

The discovery and use of medicines is just as fascinating a human scientific endeavor as space flight or the tracing of human evolution. It is also the everyday task of hundreds of thousands of pharmacists, pharmaceutical chemists and researchers worldwide.
Based on his profound knowledge of past and present paradigms in the development of medicines, Enrique Ravina takes the reader from the very beginnings of pharmacology to the multibillion-dollar business it represents today. Recounting the often spectacular successes and failures of innovative drugs as well as the people who discovered... View Details

Best Science Podcasts 2018

We have hand picked the best science podcasts for 2018. Sit back and enjoy new science podcasts updated daily from your favorite science news services and scientists.
Now Playing: TED Radio Hour

The Consequences Of Racism
What does it mean to be judged before you walk through the door? What are the consequences? This week, TED speakers delve into the ways racism impacts our lives, from education, to health, to safety. Guests include poet and writer Clint Smith, writer and activist Miriam Zoila Pérez, educator Dena Simmons, and former prosecutor Adam Foss.
Now Playing: Science for the People

#466 Wildfire
This week we're talking about fire: in particular, wildfires. How they spread and how we manage them, but also the deeper history of wildfires on our planet and how they've been shaping our world for a long, long time. We speak with Andrew Scott, Emeritus Professor of Geology at Royal Holloway, University of London, about his book "Burning Planet: The Story of Fire Through Time", learning about wildfire on our planet now and in deep history. And we catch up with Caroline Weinberg, interm executive director of the March for Science organization, about this year's march on April 14.